Rep. Pat Tiberi, R-Ohio, walks to the Capitol for a vote on Thursday, Sept. 8, 2016. (Bill Clark/CQ Roll Call)
The pharmaceutical and biotechnology industry lobbying giants ramped up their advocacy spending in the final three months of 2016, just as Congress was finalizing a new law aimed at speeding drug development and research.
The Pharmaceutical Research and Manufacturers of America dropped $4.9 million in the fourth quarter of 2016, up from $3.8 in the same quarter in 2015, a CQ analysis of new lobbying filings shows. The Biotechnology Innovation Organization spent $2.3 million to influence policymakers over the same three months, up from $2.1 million the year before.